Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
2004 1
2005 1
2007 2
2009 7
2010 13
2011 4
2012 6
2013 13
2014 8
2015 13
2016 14
2017 13
2018 6
2019 13
2020 16
2021 16
2022 12
2023 15
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Fasting-mimicking diet and hormone therapy induce breast cancer regression.
Caffa I, Spagnolo V, Vernieri C, Valdemarin F, Becherini P, Wei M, Brandhorst S, Zucal C, Driehuis E, Ferrando L, Piacente F, Tagliafico A, Cilli M, Mastracci L, Vellone VG, Piazza S, Cremonini AL, Gradaschi R, Mantero C, Passalacqua M, Ballestrero A, Zoppoli G, Cea M, Arrighi A, Odetti P, Monacelli F, Salvadori G, Cortellino S, Clevers H, De Braud F, Sukkar SG, Provenzani A, Longo VD, Nencioni A. Caffa I, et al. Among authors: cea m. Nature. 2020 Jul;583(7817):620-624. doi: 10.1038/s41586-020-2502-7. Epub 2020 Jul 15. Nature. 2020. PMID: 32669709 Free PMC article.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Among authors: cea m. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
Harnessing Immune Response in Acute Myeloid Leukemia.
Riva C, Vernarecci C, Minetto P, Goda R, Greppi M, Pesce S, Chies M, Zecchetti G, Ferro B, Maio E, Cea M, Lemoli RM, Marcenaro E, Guolo F. Riva C, et al. Among authors: cea m. J Clin Med. 2023 Sep 7;12(18):5824. doi: 10.3390/jcm12185824. J Clin Med. 2023. PMID: 37762763 Free PMC article. Review.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F. Mina R, et al. Among authors: cea m. Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14. Lancet Oncol. 2023. PMID: 36528035 Clinical Trial.
Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis.
Sacco A, Desantis V, Celay J, Giustini V, Rigali F, Savino FD, Cea M, Soncini D, Cagnetta A, Solimando AG, D'Aliberti D, Spinelli S, Ramazzotti D, Almici C, Todoerti K, Neri A, Anastasia A, Tucci A, Motta M, Chiarini M, Kawano Y, Martinez-Climent JA, Piazza R, Roccaro AM. Sacco A, et al. Among authors: cea m. Blood. 2023 May 25;141(21):2615-2628. doi: 10.1182/blood.2022019240. Blood. 2023. PMID: 36735903
Nutrients in the Prevention of Alzheimer's Disease.
Cremonini AL, Caffa I, Cea M, Nencioni A, Odetti P, Monacelli F. Cremonini AL, et al. Among authors: cea m. Oxid Med Cell Longev. 2019 Sep 4;2019:9874159. doi: 10.1155/2019/9874159. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31565158 Free PMC article. Review.
Biological Approaches in Polyhydroxyalkanoates Recovery.
Gonzalez K, Navia R, Liu S, Cea M. Gonzalez K, et al. Among authors: cea m. Curr Microbiol. 2021 Jan;78(1):1-10. doi: 10.1007/s00284-020-02263-1. Epub 2020 Oct 28. Curr Microbiol. 2021. PMID: 33112974 Review.
Biological Insights into Myeloma and Other B Cell Malignancies.
Fulciniti M, Amodio N, Cea M, Maiso P, Azab AK. Fulciniti M, et al. Among authors: cea m. Biomed Res Int. 2016;2016:5218093. doi: 10.1155/2016/5218093. Epub 2016 Feb 16. Biomed Res Int. 2016. PMID: 26989685 Free PMC article. No abstract available.
Targeting Inflammation in Primary Cardiovascular Prevention.
Carbone F, Liberale L, Bonaventura A, Cea M, Montecucco F. Carbone F, et al. Among authors: cea m. Curr Pharm Des. 2016;22(37):5662-5675. doi: 10.2174/1381612822666160822124546. Curr Pharm Des. 2016. PMID: 27549380 Review.
147 results